Known targets — ChEMBL curated mechanism
CDK1CDK10CDK11BCDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK2CDK20CDK3CDK4CDK5CDK6CDK7CDK8CDK9
The experimentally established mechanism targets of At-7519. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 known ✓ | Q00535 | 3/20 | 0.62 |
| ▸ | CDK9 known ✓ | P50750 | 2/20 | 0.62 |
| ▸ | CDK14 known ✓ | O94921 | 13/20 | 0.59 |
| ▸ | CDK2 known ✓ | P24941 | 6/20 | 0.59 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.59 |
| ▸ | CDK1 known ✓ | P06493 | 2/20 | 0.59 |
| ▸ | CDK11B known ✓ | P21127 | 1/20 | 0.59 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 0.59 |
| ▸ | CDK3 known ✓ | Q00526 | 1/20 | 0.59 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.59 |
| ▸ | CDK16 known ✓ | Q00536 | 1/20 | 0.59 |
| ▸ | CDK17 known ✓ | Q00537 | 1/20 | 0.59 |
| ▸ | CDK18 known ✓ | Q07002 | 1/20 | 0.59 |
| ▸ | CDK13 known ✓ | Q14004 | 1/20 | 0.59 |
| ▸ | CDK15 known ✓ | Q96Q40 | 1/20 | 0.59 |
| ▸ | CDK19 known ✓ | Q9BWU1 | 1/20 | 0.59 |
| ▸ | CDK12 known ✓ | Q9NYV4 | 1/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.62 |
| ▸ | CCNY | Q8ND76 | 13/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-7519 SCHEMBL955568 | 0.96 | CDK5 (0.67) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL953647 | 0.95 | CDK5 (0.66) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL31046986 | 0.95 | CDK5 (0.66) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL16318377 | 0.93 | CDK5 (0.61) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL1072294 | 0.93 | CDK5 (0.61) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL8044614 | 0.92 | CDK5 (0.60) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL1286740 | 0.89 | CDK2 (0.67) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL1286739 | 0.85 | CDK5 (0.53) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL8263051 | 0.85 | CDK14 (0.52) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL1286714 | 0.84 | CDK5 (0.53) | CDK5CCNT1CDK9CDK5R1CDK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846393-B1 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8293767-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110002879-A1 | Combinations of Pyrazole Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1845974-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1846393-A2 | 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845975-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845973-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274616-A1 | 4-(2,6-DICHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE ACID ADDITION SALTS AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP4K1 | CDK5 49/4885CDK9 150/4885CDK14 295/4885 |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | CDK1, CCNO, CDK14 | CDK5 24/4885CDK9 41/4885CDK14 3/4885 |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | CDK9, CDK1, CDK19 | CDK5 24/4885CDK9 1/4885CDK14 6/4885 |
| US-20110002879-A1 | Combinations of Pyrazole Kinase Inhibitors | ERBB4, GRK4, ROS1 | CDK5 180/4885CDK9 94/4885CDK14 10/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | CDK5 1513/4885CDK9 1753/4885CDK14 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.